Therapeutic compounds

1. A compound of formula I:

wherein:

A is

 wherein each Z 3a is independently selected from H or Z 3 ;

R 1 is a bicyclic-heteroaryl or tricyclic-heteroaryl, wherein the bicyclic-heteroaryl or tricyclic-heteroaryl has 4-9 carbon atoms and 1-5 heteroatoms selected from nitrogen, sulfur, and oxygen, and wherein the bicyclic-heteroaryl or tricyclic-heteroaryl of R 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 4 groups;

R 2 is phenyl optionally substituted with 1, 2, or 3 Z 5 groups;

each R 3a and R 3b is independently selected from H, halogen, (C 1 -C 3 )alkyl, and (C 1 -C 3 )haloalkyl, or R 3a is selected from H, (C 1 -C 3 )alkyl and (C 1 -C 3 )haloalkyl and R 3b is selected from —OH and —CN;

Z 1 is phenyl, monocyclic-heteroaryl or bicyclic-heterocycle, wherein the monocyclic-heteroaryl or bicyclic-heterocycle has 4-8 carbon atoms and 1-3 heteroatoms and, wherein any phenyl, monocyclic-heteroaryl or bicyclic-heterocycle of Z 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1a or Z 1b ;

each Z 1a is independently selected from halogen, —CN, —OR n1 , —OC(O)R p1 , —OC(O)NR q1 R r1 , —SR n1 , —S(O)R p1 , —S(O) 2 OH, —S(O) 2 R p1 , —S(O) 2 NR q1 R r1 , —NR q1 R r1 , —NR n1 COR p1 , —NR n1 CO 2 R p1 , —NR n1 CONR q1 R r1 , —NR n1 S(O) 2 R p1 , —NR n1 S(O) 2 OR p1 , —NR n1 S(O) 2 NR q1 R r1 , NO 2 , —C(O)R n1 , —C(O)OR n1 , —C(O)NR q1 R r1 and —S(O) 2 NR n1 COR p1 ;

each Z 1b is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 1b is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups;

each Z 1c is independently selected from halogen, —CN, —OR n2 , —OC(O)R p2 , —OC(O)NR q2 R r2 , —SR n2 , —S(O)R p2 , —S(O) 2 OH, —S(O) 2 R p2 , —S(O) 2 NR q2 R r2 , —NR q2 R r2 , —NR n2 COR p2 , —NR n2 CO 2 R p2 , —NR n2 CONR q2 R r2 , —NR n2 S(O) 2 R p2 , —NR n2 S(O) 2 OR p2 , —NR n2 S(O 2 NR q2 R r2 , NO 2 , —C(O)R n2 , —C(O)OR n2 , and —C(O)NR q2 R r2 ;

each Z 1d is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl and (C 1 -C 8 )haloalkyl;

each R n1 is independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, and (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R n1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups;

each R p1 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, and (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R p1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups;

R q1 and R r1 are each independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of R q1 or R r1 is optionally substituted with 1, 2, 3, 4, or 5 Z 1c groups;

each R n2 is independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl;

each R p2 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl;

R q2 and R r2 are each independently selected from H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )haloalkyl and (C 1 -C 8 )heteroalkyl;

Z 2 is selected from —OR s3 —OC(O)R p3 , —OC(O)NR q3 R r3 , —SR n3 , —S(O)R p3 , —S(O) 2 R p3 , —S(O) 2 NR q3 R r3 , —NR q3 R r3 , —NR n3 COR p3 , —NR n3 CO 2 R p3 , —NR n3 S(O) 2 R p3 , —NR n3 S(O) 2 OR p3 and —NR n3 S(O) 2 NR q3 R r3 ;

each Z 2a is independently selected from halogen, —CN, —OR n4 , —OC(O)R p4 , —OC(O)NR q4 R r4 , —SR n4 , —S(O)R p4 , —S(O) 2 OH, —S(O) 2 R p4 , —S(O) 2 NR q4 R r4 , —NR q4 R r4 , —NR n4 COR p4 , —NR n4 CO 2 R p4 , —NR n4 CONR q2 R r4 , —NR n4 S(O) 2 R p4 , —NR n4 S(O) 2 OR p4 , —NR n4 S(O) 2 NR q4 R r4 , NO 2 , —C(O)R n4 , —C(O)OR n4 , and —C(O)NR q4 R r4 ,

each Z 2b is independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )heteroalkyl and (C 1 -C 4 )haloalkyl;

each Z 2c is independently selected from halogen, —CN, —OR n4 , —OC(O)R p4 , —OC(O)NR q4 R r4 , —SR n4 , —S(O)R p4 , —S(O) 2 OH, —S(O) 2 R p4 , —S(O) 2 NR q4 R r4 , —NR q4 R r4 , —NR n4 COR p4 , —NR n4 CO 2 R p4 , —NR n4 CONR q4 R r4 , —NR n4 S(O) 2 R p4 , —NR n4 S(O) 2 OR p4 , —NR n4 S(O) 2 NR q4 R r4 , NO 2 , —C(O)R n4 , —C(O)OR n4 , —C(O)NR q4 R r4 ;

each R n3 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R n3 is optionally substituted with 1, 2, 3, 4, or 5 Z 2a groups;

each R p3 is independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R p3 is optionally substituted with 1, 2, 3, 4, or 5 Z 2a groups;

R q3 and R r3 are each independently selected from H, (C 1 -C 4 )alkyl, and (C 2 -C 4 )alkenyl, wherein any (C 1 -C 4 )alkyl and (C 2 -C 4 )alkenyl of R q3 or R r3 is optionally substituted with 1, 2, 3, 4, or 5 Z 2a groups, or R q3 and R r3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl selected from triazolyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidinyl wherein the triazolyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidinyl is optionally substituted with 1, 2, 3, 4, or 5 Z 2b , Z 2c , or oxo groups;

each R s3 is independently selected from (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl, wherein any (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R s3 is optionally substituted with 1, 2, 3, 4, or 5 Z 2a groups, or R s3 is (C 1 -C 4 )alkyl substituted with 1, 2, 3, 4, or 5 Z 2a groups;

each R n4 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )heteroalkyl;

each R p4 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )heteroalkyl;

R q4 and R r4 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )heteroalkyl;

each Z 3 is independently selected from halogen, (C 1 -C 4 )alkyl, —OH, —CN, (C 1 -C 4 )heteroalkyl and (C 1 -C 4 )haloalkyl;

each Z 4 is independently selected from (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, halogen, —CN, —OR n5 , —OC(O)R p5 , —OC(O)NR q5 R r5 , —SR n5 , —S(O)R p5 , —S(O) 2 OH, —S(O) 2 R p5 , —S(O) 2 NR q5 R r5 , —NR q5 R r5 , —NR n5 COR p5 , —NR n5 CO 2 R p5 , —NR n5 CONR q5 R r5 , —NR n5 S(O) 2 R p5 , —NR n5 S(O) 2 OR p5 , —NR n5 S(O) 2 NR q5 R r5 , NO 2 , —C(O)R n5 , —C(O)OR n5 , —C(O)NR q5 R r5 and —B(OR q5 )(OR r5 ), wherein any (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl and (C 2 -C 8 )alkynyl of Z 4 is optionally substituted with 1, 2, 3, 4, or 5 Z 4a groups;

each Z 4a is independently selected from halogen, —CN, —OR n6 , —OC(O)R p6 , —OC(O)NR q6 R r6 , —SR n6 , —S(O)R p6 , —S(O) 2 OH, —S(O) 2 R p6 , —S(O) 2 NR q6 R r6 , —NR q6 R r6 , —NR n6 COR p6 , —NR n6 CO 2 R p6 , —NR n6 CONR q6 R r6 , —NR n6 S(O) 2 R p6 , —NR n6 S(O) 2 OR p6 , —NR n6 S(O) 2 NR q6 R r6 , NO 2 , —C(O)R n6 , —C(O)OR n6 , and —C(O)NR q6 R r6 ;

each Z 4b is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of Z 4b is optionally substituted with 1, 2, 3, 4, or 5 Z 4c groups;

each Z 4c is independently selected from halogen, —CN, —OR n7 , —OC(O)R p7 , —OC(O)NR q7 R r7 , —SR n7 , —S(O)R p7 , —S(O) 2 OH, —S(O) 2 R p7 , —S(O) 2 NR q7 R r7 , —NR q7 R r7 , —NR n7 COR p7 , —NR n7 CO 2 R p7 , —NR n7 CONR q7 R r7 , —NR n7 S(O) 2 R p7 , —NR n7 S(O) 2 OR p7 , NR n7 S(O) 2 NR q7 R r7 , NO 2 , —C(O)R n7 , —C(O)OR n7 , —C(O)NR q7 R r7 and (C 1 -C 4 )heteroalkyl;

each Z 4d is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl;

each R n5 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R n5 is optionally substituted with 1, 2, 3, 4, or 5 Z 4a groups;

each R p5 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R p5 is optionally substituted with 1, 2, 3, 4, or 5 Z 4a groups;

R q5 and R r5 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R q5 or R r5 is optionally substituted with 1, 2, 3, 4, or 5 Z 4a groups;

each R n6 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R n6 is optionally substituted with 1, 2, 3, 4, or 5 Z 4c groups;

each R p6 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R p6 is optionally substituted with 1, 2, 3, 4, or 5 Z 4c groups;

R q6 and R r6 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, and (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl of R q6 or R r6 is optionally substituted with 1, 2, 3, 4, or 5 Z 4c groups;

each R n7 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )heteroalkyl;

each R p7 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )haloalkyl and (C 1 -C 4 )heteroalkyl;

R q7 and R r7 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 ) haloalkyl and (C 1 -C 4 ) heteroalkyl,

each Z 5 is independently selected from (C 1 -C 6 )alkyl, halogen, —CN, and —OR n8 , wherein any (C 1 -C 6 )alkyl of Z 5 is optionally substituted with 1, 2, 3, 4, or 5 halogen; and

each R n8 is independently selected from H, (C 1 -C 3 )alkyl, and (C 1 -C 3 )haloalkyl;

or a salt thereof.

2. The compound of claim 1 , or a salt thereof, wherein R 3a and R 3b are each H.

3. The compound of claim 1 , or a salt thereof, wherein R 2 is 3,5-difluorophenyl.

4. The compound of claim 1 which is a compound of formula Ie:

or a salt thereof.

5. The compound of claim 1 , or a salt thereof, wherein each Z 1a is independently halogen, —OR n1 , —S(O) 2 NR q1 R r1 , —NR q1 R r1 , —NR n1 S(O) 2 R p1 or —C(O)NR q1 R r1 , and each Z 1b is (C 1 -C 3 )alkyl, wherein any (C 1 -C 3 )alkyl of Z 1b is optionally substituted with one Z 1c group.

6. The compound of claim 1 , or a salt thereof, wherein Z 1 is:

7. The compound of claim 1 , or a salt thereof, wherein Z 2 is —NR q3 R r3 .

8. The compound of claim 1 , or a salt thereof, wherein R q3 and R r3 are each independently selected from H and (C 1 -C 4 )alkyl wherein any (C 1 -C 4 )alkyl of R q3 or R r3 is optionally substituted with 1, 2, 3, 4, or 5 Z 2a groups, or R q3 and R r3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl selected from triazolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidinyl wherein the triazolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidinyl is optionally substituted with 1, 2, 3, 4, or 5 Z 2b , Z 2c , or oxo groups.

9. The compound of claim 1 , or a salt thereof, wherein Z 2 is selected from:

10. The compound of claim 1 , or a salt thereof, wherein R 1 is a bicyclic-heteroaryl, wherein the bicyclic-heteroaryl of R 1 contains at least one partially unsaturated ring.

11. The compound of claim 1 , or a salt thereof, wherein each Z 4 is independently selected from (C 1 -C 6 )alkyl and halogen, wherein any (C 1 -C 6 )alkyl of Z 3 is optionally substituted with 1, 2, 3, 4, or 5 halogen.

12. The compound of claim 1 , or a salt thereof, wherein R 1 is selected from:

13. A compound, in which the compound is:

and pharmaceutically acceptable salts thereof.

14. A compound of formula If:

A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z 1 group, one Z 2 group, and optionally substituted with Z 3 group;

R 1 is

Z 1 is phenyl, pyradinyl, indazolyl, or triazolopyridinyl, wherein any phenyl, pyradinyl, indazolyl, or triazolopyridinyl, of Z 1 is optionally substituted with 1 to 3 substituents independently selected from (C 1 -C 8 )alkyl, oxo, halogen, —C(O)NH 2 , —NHS(O) 2 CH 3 , or —N(COCH 3 )(S(O) 2 CH 3 );

Z 2 is —NR q3 R r3 , —NHCOR p3 , —NHCO 2 R p3 , —NHS(O) 2 R p3 , —NHS(O) 2 OR p3 , —NHS(O) 2 NR q3 R r3 , or —SCH 3 ;

R q3 and R r3 are each independently H or (C 1 -C 4 )alkyl, wherein any (C 1 -C 4 )alkyl of R q3 or R r3 is optionally substituted with —OH, or R q3 and R r3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl selected from triazolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidin 1 wherein the triazolyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, isoindolinyl, 2-oxa-6-azaspiro[3.3]heptanyl, and imidazolidinyl, is optionally substituted with 1 to 3 substituents independently selected from (C 1 -C 4 )alkyl, —OH, —NH 2 , or oxo;

R p3 is (C 1 -C 4 )alkyl or (C 1 -C 4 )haloalkyl; and

each Z 3 is independently halogen, (C 1 -C 4 )alkyl, —OH, —CN, (C 1 -C 4 )heteroalkyl or (C 1 -C 4 )haloalkyl;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A method for treating an HIV infection in a mammal comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the mammal.

17. A method for treating an HIV infection in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.